DJS Antibodies

DJS Antibodies is a private, pre-revenue biotech specializing in creating antibody drugs for challenging membrane protein targets, primarily GPCRs, which have historically been resistant to conventional antibody approaches. Its core technology, the HEPTAD platform, is designed to generate functional antibodies by immunizing with stabilized native target conformations. The company is advancing a pipeline of early-stage, pre-clinical programs, positioning it to address significant opportunities in immunology and oncology, though it faces typical development risks and platform validation hurdles.

HEPTAD (Hyperstable Evolving Peptide-Tethered Antigen Display) platform for discovering functional antibodies against difficult membrane protein targets like GPCRs by immunizing with stabilized native conformation peptide mimics.

DJS Antibodies competes in the niche of difficult-to-drug target discovery, facing competition from other biotechnology companies with specialized antibody platforms (e.g., AbCellera, Adagene, Bicycle Therapeutics) and large pharma internal efforts. Its direct competitors are other private or public biotechs specifically focused on GPCR antibody discovery, such as Tectonic Therapeutic and G7 Therapeutics, making differentiation through platform efficacy and speed critical.